AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
MaxCyte Updates 2025 Revenue Guidance to $29.5M-$32.5M Amid Customer Program Consolidation
ByAinvest
Thursday, Aug 7, 2025 3:48 am ET1min read
MaxCyte has revised its 2025 core revenue guidance to $29.5M-$32.5M due to customer program consolidation. In Q2 2025, the company reported financial results in line with expectations and highlighted growth in a challenging end market, as well as the signing of two new strategic platform agreements.
MaxCyte, Inc. (MXCT), a leading cell-engineering focused company, has revised its 2025 core revenue guidance to $29.5 million to $32.5 million due to customer program consolidation. The company reported financial results for the second quarter of 2025 in line with expectations, demonstrating growth in a challenging end market. Additionally, MaxCyte highlighted the signing of two new strategic platform agreements [2].During the second quarter of 2025, MaxCyte's core business revenue reached $8.2 million, an increase of 8% over the second quarter of 2024. The company's total revenue for the period was $8.5 million, a decrease of 18% compared to the second quarter of 2024. This decline was primarily due to the timing variability of SPL Program-related revenue milestones and royalties. The company added two new SPL clients, Adicet Bio and Anocca AB, in July, and also signed TG Therapeutics in the first quarter [2].
MaxCyte's strategic focus on expanding its platform technology's reach and advancing cell therapeutics continues to drive its growth. The company's revised guidance reflects its ongoing efforts to consolidate customer programs and capitalize on market opportunities. As the cell engineering sector evolves, MaxCyte's platform technologies remain a key enabler for the discovery, development, and commercialization of next-generation cell therapeutics [2].
References:
[1] https://seekingalpha.com/news/4480980-veracyte-raises-2025-revenue-guidance-to-504m-as-decipher-volumes-surge-and-strategic
[2] https://www.globenewswire.com/news-release/2025/08/06/3128677/0/en/MaxCyte-Reports-Second-Quarter-2025-Financial-Results-and-Updates-Full-Year-2025-Guidance.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet